Lower triglycerides
Pro Research Analysisby 
Searched over 200M research papers for "lower triglycerides"
Lowering Triglycerides: Effective Strategies and Their Impact on Cardiovascular Health
Triglyceride-Lowering Therapies and Cardiovascular Risk Reduction
Lipid-Lowering Therapeutic Classes
Research has shown that therapies primarily targeting triglyceride reduction, such as fibrates, niacin, and marine-derived omega-3 fatty acids, can lower the risk of major vascular events. A comprehensive meta-regression analysis of randomized controlled trials revealed that a 1 mmol/L reduction in triglycerides is associated with a 16% relative risk reduction in major vascular events, although this effect is less pronounced when the influential REDUCE-IT trial is excluded . Notably, high-dose eicosapentaenoic acid (EPA) from omega-3 fatty acids has demonstrated a significant 7% relative risk reduction per gram per day .
Probiotics and Triglyceride Reduction
Supplementation with specific probiotic strains, such as Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032, has been shown to significantly lower serum triglycerides by 20% in hypertriglyceridemic individuals. This effect is partly attributed to increased levels of apolipoprotein A-V (apoA-V) and reductions in various plasma metabolites . Similar results were observed in animal studies, where these probiotics lowered triglycerides by upregulating genes involved in lipid metabolism .
Plant Sterols and Omega-3 Fatty Acids
A low-fat spread enriched with plant sterols and fish omega-3 fatty acids has been found to reduce serum triglycerides by 10.6% and LDL-cholesterol by 5.2% in individuals with modest hypercholesterolemia and hypertriglyceridemia. This intervention also led to significant decreases in other lipid parameters, including total cholesterol and apolipoproteins .
Mechanistic Insights and Clinical Trials
REDUCE-IT and STRENGTH Trials
The REDUCE-IT trial highlighted the benefits of icosapent ethyl (a purified EPA formulation) in reducing cardiovascular events by 25%, independent of its triglyceride-lowering effects. This suggests that the cardiovascular benefits of EPA may be due to its broader biological actions rather than just lowering triglycerides . Conversely, the STRENGTH trial, which tested mixed omega fatty acids, did not show a reduction in cardiovascular risk despite effective triglyceride lowering, contributing to skepticism about the efficacy of triglyceride-lowering therapies alone .
Pemafibrate and Vupanorsen
Pemafibrate, a selective peroxisome proliferator-activated receptor α modulator, significantly reduced triglycerides and other lipid levels but did not lower the incidence of cardiovascular events in patients with type 2 diabetes and hypertriglyceridemia . Similarly, vupanorsen, an antisense drug targeting ANGPTL3, effectively reduced triglycerides and atherogenic lipoproteins but did not improve glycemic parameters or hepatic fat fraction .
Conclusion
While lowering triglycerides can contribute to reducing cardiovascular risk, the overall effectiveness of this strategy may depend on the specific agents used and their broader biological effects. High-dose EPA has shown promising results, whereas other triglyceride-lowering therapies have yielded mixed outcomes. Future large-scale trials are needed to provide definitive evidence on the cardiovascular benefits of triglyceride reduction.
Sources and full results
Most relevant research papers on this topic